<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008797</url>
  </required_header>
  <id_info>
    <org_study_id>E7386-J081-102</org_study_id>
    <nct_id>NCT04008797</nct_id>
  </id_info>
  <brief_title>A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor</brief_title>
  <official_title>An Open-label Phase 1b Study of E7386 in Combination With Other Anticancer Drug in Subjects With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability and to determine
      the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">March 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 0 (Cycle length is 6 or 7 days) up to Cycle 1 (Cycle length is 28 days)</time_frame>
    <description>DLT will be defined as any of the events that are considered by the investigator to be at least possibly related to therapy with the study medication. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment (approximately 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for E7386</measure>
    <time_frame>Cycle 0 Day 1: 0-24 hours; Cycle 0 Day 5 or Day 6: 0-48 hours (Cycle length is 6 or 7 days); Cycle 1 Day 8: 0-24 hours (Cycle length is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7386</measure>
    <time_frame>Cycle 0 Day 1: 0-24 hours; Cycle 0 Day 5 or Day 6: 0-48 hours (Cycle length is 6 or 7 days); Cycle 1 Day 8: 0-24 hours (Cycle length is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC: Area Under the Plasma Concentration Versus Time Curve for E7386</measure>
    <time_frame>Cycle 0 Day 1: 0-24 hours; Cycle 0 Day 5 or Day 6: 0-48 hours (Cycle length is 6 or 7 days); Cycle 1 Day 8: 0-24 hours (Cycle length is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent Total Body Clearance for E7386</measure>
    <time_frame>Cycle 0 Day 1: 0-24 hours; Cycle 0 Day 5 or Day 6: 0-48 hours (Cycle length is 6 or 7 days); Cycle 1 Day 8: 0-24 hours (Cycle length is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F: Apparent Volume of Distribution for E7386</measure>
    <time_frame>Cycle 0 Day 1: 0-24 hours; Cycle 0 Day 5 or Day 6: 0-48 hours (Cycle length is 6 or 7 days); Cycle 1 Day 8: 0-24 hours (Cycle length is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Best Overall Response (BOR)</measure>
    <time_frame>From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2 years)</time_frame>
    <description>BOR is defined as complete response (CR), partial response (PR), stable disease (SD), PD, and not evaluable (NE), where SD has to be achieved at &gt;= 7 weeks after the first dose. The BOR will be assessed by investigator based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for HCC part or on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for ST-part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2 years)</time_frame>
    <description>The ORR is defined as the percentage of participants with a BOR of CR or PR. The ORR will be assessed by investigator based on mRECIST for HCC part or on RECISTversion 1.1 for ST-part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2 years)</time_frame>
    <description>DCR is defined as the percentage of participants with a BOR of CR, PR, or SD. The DCR will be assessed by investigator based on mRECIST for HCC part or on RECISTversion 1.1 for ST-part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>From first dose of study drug until PD, development of unacceptable toxicity, participant requests to discontinue, withdrawal of consent or study termination (up to approximately 2 years)</time_frame>
    <description>The CBR is defined as the percentage of participants with a BOR of CR, PR, or durable SD (duration of SD &gt;=23 weeks). The CBR will be assessed by investigator based on mRECIST for HCC part or on RECISTversion 1.1 for ST-part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From first dose of study drug until PD, or death from any cause, whichever occurs first (up to approximately 2 years)</time_frame>
    <description>PFS is defined as the time from the date of the first dose to the date of the first documentation of confirmed PD or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Neoplasms</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Hepatocellular Carcinoma (HCC) Part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HCC will receive E7386 tablets, alone orally, once daily (QD) for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386 tablets, orally, QD in combination with lenvatinib capsules, orally, QD in 28-day treatment cycles until disease progression (PD), development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 will be based on the available safety data from the previous cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Solid Tumor (ST) Part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with ST (except for HCC) will receive E7386 tablets, alone orally, QD for 5 or 6 consecutive days followed by 48 hours of without treatment in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386 tablets, orally, QD in combination with lenvatinib capsules, orally in 28-day treatment cycles until PD, development of unacceptable toxicity, participant's request to discontinue, withdrawal of consent, or termination of the study program. Dose escalation of E7386 and lenvatinib will be based on the available safety data from the previous cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7386</intervention_name>
    <description>E7386, tablets, orally.</description>
    <arm_group_label>Hepatocellular Carcinoma (HCC) Part</arm_group_label>
    <arm_group_label>Other Solid Tumor (ST) Part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib, capsules, orally.</description>
    <arm_group_label>Hepatocellular Carcinoma (HCC) Part</arm_group_label>
    <arm_group_label>Other Solid Tumor (ST) Part</arm_group_label>
    <other_name>Lenvima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HCC part only:

             Participants with confirmed diagnosis of unresectable HCC with any of the following
             criteria:

               1. Histologically or cytologically confirmed diagnosis of HCC, excluding
                  fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors

               2. Clinically confirmed diagnosis of HCC according to American Association for the
                  Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology
                  and/or chronic hepatitis B or C infection

             ST part only (except for HCC ):

             Participants with histologically or cytologically confirmed diagnosis of solid tumor
             for which no alternative standard therapy or no effective therapy exists

          2. Life expectancy of &gt;=12 weeks

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          4. All AEs due to previous anti-cancer therapy have either returned to Grade 0-1 except
             for alopecia (renal/bone marrow/liver function should meet the inclusion criteria).

          5. Adequate controlled blood pressure (BP), renal function, bone marrow function, liver
             function, and serum mineral level

          6. At least one measurable lesion based on mRECIST (HCC part) or on RECIST 1.1 (ST-part)

          7. HCC part only: Child-Pugh score A

          8. HCC part only: Participants categorized to stage B (not applicable for trans arterial
             chemoembolization), or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging
             system

        Exclusion Criteria:

          1. Any of cardiac conditions as follows:

               1. Heart failure New York Heart Association (NYHA) Class II or above

               2. Unstable ischaemic heart disease (myocardial infarction within 6 months prior to
                  starting study drug, or angina requiring use of nitrates more than once weekly)

               3. Prolongation of corrected QT (QTcF) interval to greater than (&gt;) 480 millisecond
                  (msec)

               4. Left ventricular ejection fraction (LVEF) &lt;50 percent (%)

          2. Known to be human immunodeficiency virus (HIV) positive

          3. Participants with proteinuria &gt;1+ on urine dipstick testing will undergo 24-h urine
             collection for quantitative assessment of proteinuria. Participants with urine protein
             &gt;=1 gram per (g/) 24 hour will be ineligible

          4. Diagnosed with meningeal carcinomatosis

          5. Participants with brain or subdural metastases are not eligible, unless they have
             completed local therapy and have discontinued the use of corticosteroids for this
             indication for at least 4 weeks before starting treatment in this study Any signs
             (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks
             before starting study treatment

          6. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring
             active treatment, including the use of oxygen

          7. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic
             International Normalized Ratio (INR) monitoring (e.g. warfarin or similar agents)

          8. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5
             teaspoon) within 3 weeks prior to the first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Inquiry Service</last_name>
    <email>eisai-chiken_hotline@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #3</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>E7386</keyword>
  <keyword>Lenvatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

